ATGE (Adtalem Global Education Inc. Common Shares)
Insider Trading Activity
Every open-market purchase and sale reported by ATGE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-12 | Stephen W. Beard | Chairman & CEO | G | — | — |
| 2025-11-14 | Evan Trent | President, Adtalem Elevate | MIXED | — | — |
| 2025-11-14 | SHARON O'KEEFE | Director | A | — | — |
| 2025-11-14 | Megan Noel | Chief Corp. Affairs Officer | A | — | — |
| 2025-11-14 | Georgette D. Kiser | Director | MIXED | — | — |
| 2025-11-14 | Sara Hill | CHRO | A | — | — |
| 2025-11-14 | Karen Sue Cox | President, Chamberlain Univ. | MIXED | — | — |
| 2025-11-14 | MICHAEL W MALAFRONTE | Director | MIXED | — | — |
| 2025-11-14 | Maurice Herrera | SVP - Chief Marketing Officer | MIXED | — | — |
| 2025-11-14 | WILLIAM W BURKE | Director | MIXED | — | — |
| 2025-11-14 | Michael Betz | Pres. Walden University & CDO | MIXED | — | — |
| 2025-11-14 | Kenneth J Phelan | Director | MIXED | — | — |
| 2025-11-14 | Donna J Hrinak | Director | MIXED | — | — |
| 2025-11-14 | Betty M. Vandenbosch | Director | MIXED | — | — |
| 2025-11-14 | Stephen W. Beard | Chairman & CEO | F | — | — |
| 2025-11-14 | DOUGLAS G. BECK | SVP, GC, Corp. Sec & ISS | MIXED | — | — |
| 2025-11-14 | LISA W WARDELL | Director | MIXED | — | — |
| 2025-11-14 | Robert J. Phelan | Chief Financial Officer | MIXED | — | — |
| 2025-11-14 | Manjunath Gangadharan | VP, Chief Accounting Officer | MIXED | — | — |
| 2025-11-14 | Scott Liles | President, Medical and Vet | MIXED | — | — |
| 2025-11-14 | William V Krehbiel | Director | MIXED | — | — |
| 2025-11-12 | Robert J. Phelan | Chief Financial Officer | F | — | — |
| 2025-11-05 | Kenneth J Phelan | Director | Buy | — | — |
| 2025-11-04 | MICHAEL W MALAFRONTE | Director | Buy | — | — |
| 2025-10-16 | Sara Hill | CHRO | F | — | — |
| 2025-09-09 | Stephen W. Beard | Chairman & CEO | F | — | — |
| 2025-08-29 | LISA W WARDELL | Director | Sell | — | — |
| 2025-08-27 | Robert J. Phelan | Chief Financial Officer | MIXED | — | — |
| 2025-08-27 | Stephen W. Beard | Chairman & CEO | MIXED | — | — |
| 2025-08-27 | Sara Hill | CHRO | MIXED | — | — |
| 2025-08-27 | Manjunath Gangadharan | VP, Chief Accounting Officer | MIXED | — | — |
| 2025-08-27 | LISA W WARDELL | Director | MIXED | — | — |
| 2025-08-27 | Michael Betz | Pres. Walden University & CDO | MIXED | — | — |
| 2025-08-27 | Maurice Herrera | SVP - Chief Marketing Officer | MIXED | — | — |
| 2025-08-27 | Evan Trent | President, Adtalem Elevate | MIXED | — | — |
| 2025-08-27 | Karen Sue Cox | President, Chamberlain Univ. | MIXED | — | — |
| 2025-08-27 | Scott Liles | President, Medical and Vet | MIXED | — | — |
| 2025-08-27 | DOUGLAS G. BECK | SVP, GC, Corp. Sec & ISS | MIXED | — | — |
| 2025-08-25 | LISA W WARDELL | Director | Sell | — | — |
| 2025-06-16 | DOUGLAS G. BECK | SVP, GC, Corp. Sec & ISS | F | — | — |
| 2025-06-06 | WILLIAM W BURKE | Director | Sell | — | — |
| 2025-05-22 | Manjunath Gangadharan | VP, Chief Accounting Officer | Sell | — | — |
| 2025-05-20 | Manjunath Gangadharan | VP, Chief Accounting Officer | F | — | — |
| 2025-04-16 | Scott Liles | President, Medical and Vet | F | — | — |
| 2025-03-07 | MICHAEL W MALAFRONTE | Director | Buy | — | — |
| 2025-02-24 | Donna J Hrinak | Director | Sell | — | — |
| 2025-02-18 | Donna J Hrinak | Director | Sell | — | — |
| 2025-02-10 | Donna J Hrinak | Director | Sell | — | — |
| 2025-02-07 | Michael Betz | Pres. Walden University & CDO | Sell | — | — |
| 2024-12-17 | MICHAEL W MALAFRONTE | Director | G | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chairman & CEO | 445,198 | — |
| — | — | 425,605 | — |
| — | Director | 101,890 | — |
| — | Former SVP, CFO | 84,391 | — |
| — | President, Chamberlain | 67,779 | — |
| — | Chief Financial Officer | 66,429 | — |
| — | SVP, GC, Corp. Sec & ISS | 48,135 | — |
| — | Director | 44,251 | — |
| — | Principal Financial Officer | 39,087 | — |
| — | Pres. - Adtalem Med & Vet | 38,718 | — |
| — | Group Pres, Adtalem Health | 33,881 | — |
| — | President, Chamberlain Univ. | 33,596 | — |
| — | Pres. Walden University & CDO | 33,286 | — |
| — | SVP, Human Resources | 31,137 | — |
| — | President, DeVry University | 27,214 | — |
| — | Director | 27,048 | — |
| — | SVP, Chief Information Officer | 25,741 | — |
| — | SVP, Corporate Affairs | 24,151 | — |
| — | President, Adtalem Elevate | 24,134 | — |
| — | SVP - Chief Marketing Officer | 20,927 | — |
| — | Director | 20,228 | — |
| — | SVP, Chief Marketing Officer | 19,438 | — |
| — | SVP, CHRO | 17,485 | — |
| — | Director | 17,481 | — |
| — | Director | 16,724 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ATGE quote page; the site-wide leaderboard is on the insider transactions hub.